KR20160098257A - 세포독성 펩티드 및 그의 접합체 - Google Patents
세포독성 펩티드 및 그의 접합체 Download PDFInfo
- Publication number
- KR20160098257A KR20160098257A KR1020167015935A KR20167015935A KR20160098257A KR 20160098257 A KR20160098257 A KR 20160098257A KR 1020167015935 A KR1020167015935 A KR 1020167015935A KR 20167015935 A KR20167015935 A KR 20167015935A KR 20160098257 A KR20160098257 A KR 20160098257A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- independently selected
- nhc
- mmol
- rti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 C*N(C(CC1C)=O)C1=O Chemical compound C*N(C(CC1C)=O)C1=O 0.000 description 85
- HPFHOMWJTISLMJ-UHFFFAOYSA-N C[n]1nnc(-c2c(C(C3)OC)cccc2)c1-c1c3cccc1 Chemical compound C[n]1nnc(-c2c(C(C3)OC)cccc2)c1-c1c3cccc1 HPFHOMWJTISLMJ-UHFFFAOYSA-N 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Cc1ccc(C)cc1 Chemical compound Cc1ccc(C)cc1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- XWKFPIODWVPXLX-UHFFFAOYSA-N Cc1ccc(C)nc1 Chemical compound Cc1ccc(C)nc1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
- IARVPDWLYVZCIN-UHFFFAOYSA-N CC(C)(C)C(ON(C(CC1)=O)C1=O)=O Chemical compound CC(C)(C)C(ON(C(CC1)=O)C1=O)=O IARVPDWLYVZCIN-UHFFFAOYSA-N 0.000 description 1
- WEMZUWMAUMYFKG-UHFFFAOYSA-N CC(C)(C)Oc(cc1)cc(N)c1/C(/C)=[O]/CC(C)(C)Oc1cc(N)c(C=O)cc1 Chemical compound CC(C)(C)Oc(cc1)cc(N)c1/C(/C)=[O]/CC(C)(C)Oc1cc(N)c(C=O)cc1 WEMZUWMAUMYFKG-UHFFFAOYSA-N 0.000 description 1
- RSRUXWAVRONSGX-NTMALXAHSA-N CC(C)(C)SC/C(/CSC)=N\OC Chemical compound CC(C)(C)SC/C(/CSC)=N\OC RSRUXWAVRONSGX-NTMALXAHSA-N 0.000 description 1
- WRVNWTLHMFPJET-UHFFFAOYSA-N CC(C)C(C(NC(CCCNC(N)=O)C(C)=O)=O)N Chemical compound CC(C)C(C(NC(CCCNC(N)=O)C(C)=O)=O)N WRVNWTLHMFPJET-UHFFFAOYSA-N 0.000 description 1
- NIXKACOKLPRDMY-UHFFFAOYSA-N CC(CC(N1C)=O)C1=O Chemical compound CC(CC(N1C)=O)C1=O NIXKACOKLPRDMY-UHFFFAOYSA-N 0.000 description 1
- IAYOJGQLVGYUIY-UHFFFAOYSA-N CC1(c(cccc2)c2NC2)NN=NC1c1c2cccc1 Chemical compound CC1(c(cccc2)c2NC2)NN=NC1c1c2cccc1 IAYOJGQLVGYUIY-UHFFFAOYSA-N 0.000 description 1
- HLGJLSZPMKRLLW-UHFFFAOYSA-N CC1N(CCI)CC2C1C2 Chemical compound CC1N(CCI)CC2C1C2 HLGJLSZPMKRLLW-UHFFFAOYSA-N 0.000 description 1
- ABSOSLVWXWHICO-UHFFFAOYSA-N CCC(C)(C)[n]1nnnc1C(C)(C)C Chemical compound CCC(C)(C)[n]1nnnc1C(C)(C)C ABSOSLVWXWHICO-UHFFFAOYSA-N 0.000 description 1
- KJMIVQYBGYRIRB-UHFFFAOYSA-N CCCNC(C(C(C)(C)COP(O)(OC)=O)O)=O Chemical compound CCCNC(C(C(C)(C)COP(O)(OC)=O)O)=O KJMIVQYBGYRIRB-UHFFFAOYSA-N 0.000 description 1
- DHDNYSGUTLETQE-UHFFFAOYSA-N CCNC(C(C)(C)CC(C)(C)C(Nc1ccc(C)cn1)=O)=O Chemical compound CCNC(C(C)(C)CC(C)(C)C(Nc1ccc(C)cn1)=O)=O DHDNYSGUTLETQE-UHFFFAOYSA-N 0.000 description 1
- DJDVXBWTQJPVLZ-UHFFFAOYSA-N CCNC(C)(C)CC(C)(C)c1cnc(C)cc1 Chemical compound CCNC(C)(C)CC(C)(C)c1cnc(C)cc1 DJDVXBWTQJPVLZ-UHFFFAOYSA-N 0.000 description 1
- URVAIEJVEWOYJK-UHFFFAOYSA-N CCNC(CCNC(C(C(C)(C)COP(O)(OC)=O)O)=O)=O Chemical compound CCNC(CCNC(C(C(C)(C)COP(O)(OC)=O)O)=O)=O URVAIEJVEWOYJK-UHFFFAOYSA-N 0.000 description 1
- WZAPNNFWVLPRAR-KFXXZZRKSA-N CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccc1)C(OC)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H]1N(C)CCCC1)=O)=O Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccc1)C(OC)=O)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H]1N(C)CCCC1)=O)=O WZAPNNFWVLPRAR-KFXXZZRKSA-N 0.000 description 1
- UKVWJYFWUNYNIZ-GRIYVSLESA-N CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccc1)c1ncccn1)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H]([C@@H]1C[C@H]2CC1)N2C(OCc(cc1)ccc1NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCCN(C(C=C1)=O)C1=O)=O)=O)=O)=O)=O)=O Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccc1)c1ncccn1)=O)OC)=O)OC)N(C)C([C@H](C(C)C)NC([C@H]([C@@H]1C[C@H]2CC1)N2C(OCc(cc1)ccc1NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CCCCCN(C(C=C1)=O)C1=O)=O)=O)=O)=O)=O)=O UKVWJYFWUNYNIZ-GRIYVSLESA-N 0.000 description 1
- WKBOPYHYAZYSHO-UHFFFAOYSA-N CN(C(CC1SC)=O)C1=O Chemical compound CN(C(CC1SC)=O)C1=O WKBOPYHYAZYSHO-UHFFFAOYSA-N 0.000 description 1
- OJEGAMHXVWSGDH-UHFFFAOYSA-N CNC(CSC)=O Chemical compound CNC(CSC)=O OJEGAMHXVWSGDH-UHFFFAOYSA-N 0.000 description 1
- LLAZQXZGAVBLRX-UHFFFAOYSA-N COC(N(C(C=C1)=O)C1=O)=O Chemical compound COC(N(C(C=C1)=O)C1=O)=O LLAZQXZGAVBLRX-UHFFFAOYSA-N 0.000 description 1
- OUDIZTOACCWIRY-GRYCIOLGSA-N C[C@H]([C@H]([C@H](CCC1)N1C(OC(C)(C)C)=O)OC)C(OC)=O Chemical compound C[C@H]([C@H]([C@H](CCC1)N1C(OC(C)(C)C)=O)OC)C(OC)=O OUDIZTOACCWIRY-GRYCIOLGSA-N 0.000 description 1
- WUNJYMIULWQVAH-HRDYMLBCSA-N C[C@H]([C@H]([C@H]1NCCC1)OC)C(OC)=O Chemical compound C[C@H]([C@H]([C@H]1NCCC1)OC)C(OC)=O WUNJYMIULWQVAH-HRDYMLBCSA-N 0.000 description 1
- NEZAEQJARBJFJC-UHFFFAOYSA-N Cc1c(C(NC)=O)nn[n]1C Chemical compound Cc1c(C(NC)=O)nn[n]1C NEZAEQJARBJFJC-UHFFFAOYSA-N 0.000 description 1
- GNBSEDONLCZTKH-UHFFFAOYSA-N NCCCCC(C=O)NC(C(Cc1ccccc1)N)=O Chemical compound NCCCCC(C=O)NC(C(Cc1ccccc1)N)=O GNBSEDONLCZTKH-UHFFFAOYSA-N 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N O=C(C=C1)NC1=O Chemical compound O=C(C=C1)NC1=O PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- BUXKULRFRATXSI-UHFFFAOYSA-N ON(C(C=C1)=O)C1=O Chemical compound ON(C(C=C1)=O)C1=O BUXKULRFRATXSI-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- A61K47/48438—
-
- A61K47/48569—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361917293P | 2013-12-17 | 2013-12-17 | |
| US61/917,293 | 2013-12-17 | ||
| PCT/US2014/070800 WO2015095301A2 (en) | 2013-12-17 | 2014-12-17 | Cytotoxic peptides and conjugates thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160098257A true KR20160098257A (ko) | 2016-08-18 |
Family
ID=52463118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167015935A Ceased KR20160098257A (ko) | 2013-12-17 | 2014-12-17 | 세포독성 펩티드 및 그의 접합체 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9988420B2 (enExample) |
| EP (2) | EP3082877B1 (enExample) |
| JP (2) | JP6636925B2 (enExample) |
| KR (1) | KR20160098257A (enExample) |
| CN (1) | CN105899526A (enExample) |
| AU (1) | AU2014364812B2 (enExample) |
| BR (1) | BR112016012538A2 (enExample) |
| CA (1) | CA2930614A1 (enExample) |
| EA (1) | EA201691251A1 (enExample) |
| ES (1) | ES2758506T3 (enExample) |
| IL (1) | IL245558B (enExample) |
| MX (1) | MX2016007865A (enExample) |
| PL (1) | PL3082877T3 (enExample) |
| PT (1) | PT3082877T (enExample) |
| SG (1) | SG11201604877UA (enExample) |
| WO (1) | WO2015095301A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015018899B1 (pt) * | 2013-02-08 | 2023-09-26 | Novartis Ag | Imunoconjugados, composição farmacêutica, anticorpos igg modificados ou fragmentos de anticorpo modificados dos mesmos e seu método de produção, e célula hospedeira |
| AU2014228489B2 (en) | 2013-03-15 | 2018-11-15 | Zymeworks Bc Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
| KR20160125361A (ko) | 2013-12-27 | 2016-10-31 | 자임워크스 인코포레이티드 | Ｖａｒ２ｃｓａ－약물 접합체 |
| DK3086815T3 (da) | 2013-12-27 | 2022-05-23 | Zymeworks Inc | Sulfonamidholdige forbindelsessystemer til lægemiddelkonjugater |
| EA201691827A1 (ru) * | 2014-03-12 | 2017-01-30 | Новартис Аг | Конкретные участки для модификации антител с целью получения иммуноконъюгатов |
| SG11201609462RA (en) | 2014-06-13 | 2016-12-29 | Novartis Ag | Auristatin derivatives and conjugates thereof |
| RU2723651C2 (ru) | 2014-09-17 | 2020-06-17 | Займворкс Инк. | Цитотоксические и антимитотические соединения и способы их применения |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| WO2017194593A1 (en) | 2016-05-11 | 2017-11-16 | Ge Healthcare Bioprocess R&D Ab | Method of cleaning and/or sanitizing a separation matrix |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| CN109311949B (zh) | 2016-05-11 | 2022-09-16 | 思拓凡生物工艺研发有限公司 | 储存分离基质的方法 |
| US10513537B2 (en) | 2016-05-11 | 2019-12-24 | Ge Healthcare Bioprocess R&D Ab | Separation matrix |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| US10517958B2 (en) | 2016-10-04 | 2019-12-31 | Zymeworks Inc. | Compositions and methods for the treatment of platinum-drug resistant cancer |
| JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
| TW202014209A (zh) * | 2018-06-20 | 2020-04-16 | 瑞士商諾華公司 | 用於消融造血幹細胞之抗體藥物軛合物 |
| EP3883914A4 (en) * | 2018-11-23 | 2022-04-06 | Wuxi Biologics Ireland Limited | ORTHOPHTHALALDEHYDE-CONTAINING LINKERS AND METHODS FOR PRODUCTION OF ANTIBODY-DRUG CONJUGATE |
| CA3170633A1 (en) * | 2020-03-09 | 2021-09-16 | David Goeddel | Efficient preparation of dolastatin and auristatin analogs through a common intermediate |
| US20230181756A1 (en) | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
| WO2022154127A1 (ja) * | 2021-01-18 | 2022-07-21 | 味の素株式会社 | 化合物またはその塩、およびそれらにより得られる抗体 |
| EP4420682A1 (en) * | 2021-10-12 | 2024-08-28 | Chengdu Scimount Pharmatech Co., Ltd. | Highly-stable targeted linker-drug conjugate |
| TW202412762A (zh) * | 2022-07-27 | 2024-04-01 | 香港商祐方有限公司 | 奧瑞他汀衍生物及其結合物 |
| WO2024152000A1 (en) * | 2023-01-13 | 2024-07-18 | The Trustees Of The University Of Pennsylvania | Disruptable linker compositions, switchable bispecific t cell nanoengager (switch-bite) compositions comprising the same, and methods of use thereof |
| CN121240890A (zh) | 2023-04-18 | 2025-12-30 | 阿斯利康(瑞典)有限公司 | 包含可裂解接头的缀合物 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| AU662551B2 (en) | 1991-08-09 | 1995-09-07 | Teikoku Hormone Mfg. Co., Ltd. | Novel tetrapeptide derivative |
| CA2173150C (en) | 1993-10-01 | 2004-11-30 | Kyoichi Sakakibara | Novel peptide derivatives |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| AU704973B2 (en) | 1995-04-21 | 1999-05-13 | Teikoku Hormone Mfg. Co., Ltd. | Novel peptide derivatives |
| WO1998056915A2 (en) | 1997-06-12 | 1998-12-17 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
| US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| US7803915B2 (en) | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
| US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| CN107213469A (zh) | 2003-11-06 | 2017-09-29 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| EP3505191A1 (en) * | 2004-11-12 | 2019-07-03 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the n terminus |
| WO2006065533A2 (en) | 2004-11-29 | 2006-06-22 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| BRPI0612529A2 (pt) | 2005-06-20 | 2010-11-23 | Psma Dev Company Llc | conjugados de anticorpo-medicamento de psma |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| WO2007103288A2 (en) | 2006-03-02 | 2007-09-13 | Seattle Genetics, Inc. | Engineered antibody drug conjugates |
| AR059900A1 (es) | 2006-03-17 | 2008-05-07 | Genentech Inc | Anticuerpos anti-tat226 e inmunoconjugados |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| DK2265283T3 (da) | 2008-03-18 | 2014-10-20 | Seattle Genetics Inc | Auristatin-lægemiddel-linker-konjugater |
| ES2553874T3 (es) | 2010-09-29 | 2015-12-14 | Seattle Genetics, Inc. | N-Carboxialquil-auristatinas y su uso |
| CA2815363C (en) | 2010-10-22 | 2020-07-14 | Seattle Genetics, Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
| DK2678037T3 (en) | 2011-02-25 | 2015-03-09 | Lonza Ag | Branched linker for protein pharmaceutical conjugates |
| JP6023097B2 (ja) | 2011-03-16 | 2016-11-09 | シアトル ジェネティックス， インコーポレイテッド | Ｎカルボキシアルキルオーリスタチンおよびその使用 |
| AU2012244673A1 (en) | 2011-04-21 | 2013-11-28 | Seattle Genetics, Inc. | Novel binder-drug conjugates (ADCs) and their use |
| KR102179369B1 (ko) | 2011-05-27 | 2020-11-16 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도 |
| CN104185477B (zh) | 2011-11-17 | 2017-05-24 | 辉瑞公司 | 细胞毒性肽及其抗体‑药物缀合物 |
| JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
| MX2014014894A (es) * | 2012-06-04 | 2015-02-20 | Irm Llc | Metodos de marcado especifico del sitio y moleculas producidas mediante los mismos. |
| BR112015018899B1 (pt) * | 2013-02-08 | 2023-09-26 | Novartis Ag | Imunoconjugados, composição farmacêutica, anticorpos igg modificados ou fragmentos de anticorpo modificados dos mesmos e seu método de produção, e célula hospedeira |
-
2014
- 2014-12-17 US US15/104,727 patent/US9988420B2/en active Active
- 2014-12-17 WO PCT/US2014/070800 patent/WO2015095301A2/en not_active Ceased
- 2014-12-17 EP EP14835606.6A patent/EP3082877B1/en not_active Not-in-force
- 2014-12-17 BR BR112016012538A patent/BR112016012538A2/pt not_active Application Discontinuation
- 2014-12-17 PT PT148356066T patent/PT3082877T/pt unknown
- 2014-12-17 CN CN201480068696.XA patent/CN105899526A/zh active Pending
- 2014-12-17 EP EP19193628.5A patent/EP3753578A1/en not_active Withdrawn
- 2014-12-17 AU AU2014364812A patent/AU2014364812B2/en not_active Ceased
- 2014-12-17 JP JP2016540522A patent/JP6636925B2/ja not_active Expired - Fee Related
- 2014-12-17 CA CA2930614A patent/CA2930614A1/en not_active Abandoned
- 2014-12-17 EA EA201691251A patent/EA201691251A1/ru unknown
- 2014-12-17 SG SG11201604877UA patent/SG11201604877UA/en unknown
- 2014-12-17 PL PL14835606T patent/PL3082877T3/pl unknown
- 2014-12-17 ES ES14835606T patent/ES2758506T3/es active Active
- 2014-12-17 KR KR1020167015935A patent/KR20160098257A/ko not_active Ceased
- 2014-12-17 MX MX2016007865A patent/MX2016007865A/es active IP Right Grant
-
2016
- 2016-05-09 IL IL245558A patent/IL245558B/en not_active IP Right Cessation
-
2018
- 2018-04-24 US US15/961,531 patent/US10392421B2/en active Active
-
2019
- 2019-06-12 US US16/439,204 patent/US10787480B2/en active Active
- 2019-09-27 JP JP2019176561A patent/JP2020023514A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201604877UA (en) | 2016-07-28 |
| EA201691251A1 (ru) | 2016-11-30 |
| PT3082877T (pt) | 2019-12-03 |
| US20160311853A1 (en) | 2016-10-27 |
| AU2014364812A1 (en) | 2016-07-07 |
| WO2015095301A3 (en) | 2015-09-03 |
| JP2017503777A (ja) | 2017-02-02 |
| JP6636925B2 (ja) | 2020-01-29 |
| CA2930614A1 (en) | 2015-06-25 |
| MX2016007865A (es) | 2017-01-11 |
| IL245558B (en) | 2020-01-30 |
| ES2758506T3 (es) | 2020-05-05 |
| BR112016012538A2 (pt) | 2017-09-26 |
| US10392421B2 (en) | 2019-08-27 |
| US20190382441A1 (en) | 2019-12-19 |
| EP3753578A1 (en) | 2020-12-23 |
| IL245558A0 (en) | 2016-06-30 |
| JP2020023514A (ja) | 2020-02-13 |
| US9988420B2 (en) | 2018-06-05 |
| WO2015095301A2 (en) | 2015-06-25 |
| EP3082877A2 (en) | 2016-10-26 |
| PL3082877T3 (pl) | 2020-02-28 |
| AU2014364812B2 (en) | 2017-05-25 |
| US10787480B2 (en) | 2020-09-29 |
| US20180244717A1 (en) | 2018-08-30 |
| EP3082877B1 (en) | 2019-08-28 |
| CN105899526A (zh) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6636925B2 (ja) | 細胞障害性ペプチドおよびその抱合体 | |
| EP3154997B1 (en) | Auristatin derivatives and conjugates thereof | |
| JP6498773B2 (ja) | ベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法 | |
| JP2018502131A (ja) | ヘテロアリーレン架橋したベンゾジアゼピン二量体、そのコンジュゲート、ならびに製造および使用方法 | |
| JP2022533215A (ja) | 親水性基を含むリンカーを有する抗体薬剤コンジュゲート | |
| KR20240067085A (ko) | 항체 약물 접합체에 사용하기 위한 링커 | |
| TW201836645A (zh) | 具有酵素可裂解基團的細胞毒性藥劑之前藥 | |
| JP2018528161A (ja) | Ｋｓｐ阻害剤との部位特異的均一複合体 | |
| WO2017191579A1 (en) | Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase | |
| KR102858995B1 (ko) | 설포말레이미드계 링커 및 상응하는 컨쥬게이트 | |
| JP7023933B2 (ja) | セコ－シクロプロパピロロインドール化合物、その抗体－薬物コンジュゲート、ならびに製造および使用方法 | |
| JP2026504840A (ja) | リンカー、薬物リンカー、およびそれらの複合体、ならびにそれらを使用する方法 | |
| TW202506691A (zh) | Ｓｔｉｎｇ促效劑化合物及其結合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20160615 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20191212 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20210324 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20210615 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20210324 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |